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Abstract
Background: The effect of cardiac resynchronization therapy (CRT) on systemic inflamma-
tion and neurohormonal alterations associated with heart failure is not well characterized.
Accordingly, we aimed to assess the long term effects of CRT on systemic inflammation and
neurohormonal factors in heart failure patients.
Methods and results: In 47 HF patients (NYHA III–IV) we evaluated, at baseline and after
one year of CRT: TNF-a, TNF soluble receptors (sTNFR1 and sTNFR2), insulin-like growth
factor-1a (IGF-1a), adiponectin, norepinephrine, pro-atrial natriuretic peptide (pro-ANP),
N-terminal-pro-brain natriuretic peptide (NT-proBNP) and angiotensin II, NYHA functional
class, quality of life (the Minnesota Living with Heart Failure questionnaire), a 6-minute walk
test and an echocardiogram. Long-term CRT decreased activation of renin–angiotensin sys-
tem (RAS) only in patients with reverse remodelling. It failed to prevent a decline in adiponectin
levels, regardless of reverse remodelling. NT-proBNP remained unchanged in patients with
reverse remodelling, whereas its levels increased in those without reverse remodelling. IGF-1a
increased with CRT, whereas CRT had no effect on pro-ANP and inflammatory markers.
Conclusions: Long-term CRT is associated with decreased RAS activation and stabilization
of NT-proBNP in heart failure patients with reverse remodelling. Long-term CRT, with or
without reverse remodelling, does not affect systemic inflammation and fails to prevent
a decline in adiponectin. (Cardiol J 2009; 16, 6: 545–552)
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Introduction
Cardiac resynchronization therapy (CRT) is an
established treatment for those patients with New
York Heart Association (NYHA) class III/IV chronic
systolic heart failure (CHF) and left ventricular (LV)
dyssynchrony, as evidenced by a prolonged QRS
duration beyond 120 ms [1].
By restoring co-ordinated contraction, CRT
promotes LV reverse remodelling and improves
symptoms, exercise capacity and quality of life in
patients with CHF [1]. Several animal studies and
clinical pilot trials have suggested that down-regu-
lation of inflammatory cytokines may improve car-
diac performance [2]. The effect of CRT on systemic
inflammation and neurohormonal alterations asso-
ciated with CHF is not well understood [2–6].
Accordingly, the present study aims to assess
the long-term (12 months) effects of CRT on the
systemic inflammation and neurohormonal factors
in CHF patients with NYHA III–IV functional class.
In addition, we evaluated whether 1-year CRT in-
fluence on the neurohormonal pattern was differ-
ent in patients who developed reverse remodel-
ling (responders) from those who did not (non-
-responders).
Methods
Study population and protocol
In this prospective randomized study, we en-
rolled 60 CHF patients referred to our institute from
January 2007 to December 2008 for biventricular
pacemaker implantation. Patients had an advanced
CHF (NYHA III–IV functional class) due to dilated
cardiomyopathy of any etiology, with a left ventricu-
lar ejection fraction (LVEF) < 35% [7] and QRS
duration ≥ 120 ms. All patients had been receiving
optimal medical therapy for at least three months
prior to enrolment.
Exclusion criteria were: previous pacemaker
implantation, significant valvular disease requiring
surgical correction, acute myocarditis, acute coro-
nary syndrome within three months of enrolment,
and severe chronic obstructive pulmonary disease.
Patients had no clinical evidence of inflammatory,
neoplastic, or metabolic diseases as assessed by
clinical history, examination and laboratory tests.
The study was approved by the Institutional
Review Board and Local Ethical Committee. In-
formed consent was obtained from each patient.
Eight patients refused to participate in the
study and five were lost to follow-up. Thus, 47 CHF
patients who received biventricular pacemaker
implantation were studied.
Assessment of NYHA functional class, quality
of life (QoL) using the Minnesota Living with Heart
Failure questionnaire, a 6-minute walk test (WT)
and an echocardiogram were performed at base-
line (before pacemaker implantation) and after
12 months of CRT therapy.
Measurement of systemic inflammation
and neurohormonal alterations
After a 30-minute bed rest, blood samples were
collected to measure serum TNF-a, TNF soluble
receptors (sTNFR1a and sTNFR2), insulin-like
growth factor-1a (IGF-1a), adiponectin, norepine-
phrine, pro-atrial natriuretic peptide (pro-ANP),
N-terminal-pro-brain natriuretic peptide (NT-proBNP)
and angiotensin II. Blood samples were collected
before biventricular implantation and after
12 months of CRT.
To measure TNF-a, sTNFR1, sTNFR2, IGF-1a,
adiponectin, norepinephrine, and angiotensin II,
10 mL of venous blood was collected in a sterile tube
containing EDTA at 4°C, and rapidly separated af-
ter centrifugation. For pro-ANP and NT-proBNP
measurement, 7 mL of venous blood was collected
in an ice-chilled tube containing EDTA and apro-
tinin (Trasylol, Bayer; 550 kallicrein inhibiting
units). All samples were centrifuged at 1,700 g for
20 min at 4°C and stored at –20°C until analyzed.
All measurements were performed in duplicates.
Solid phase enzyme amplified sensitivity im-
munoassay was used to measure plasma levels of
IGF-1a, TNFa, sTNFR1 and sTNFR2 (BIOSOURCE
Europe S.A., Nuvelles, Belgium). Plasma levels of
adiponectin were measured using the Mediagnost
kit ELISA (Reutlingen, Germany). Plasma levels of
NT-proBNP and pro-ANP were measured using
a competitive enzyme immunoassay (Biomedica
Gruppe, Vienna, Austria). Plasma levels of nore-
pinephrine were measured using 125I norepine-
phrine/epinephrine RIA (DRG Instruments GmbH,
Germany). Plasma levels of angiotensin II were
measured using TEMA Ricerca srl (Bologna, Italy).
Creatinine serum levels were measured in all
participants, as an estimate of renal function.
Echocardiography
Standard echocardiography including Doppler
was performed using a commercially available sys-
tem (Vivid 7; General Electric-Vingmed, Milwaukee,
Wisconsin, USA). Left ventricular end-diastolic
(LVEDV), end-systolic (LVESV) volumes and
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LVEF were calculated using the biplane Simpson’s
rule as an average of at least three measurements
and then indexed to body surface area, and reported
as LVEDVi (indexed LVEDV) and LVESVi (indexed
LVESV) [8]. Patients were defined as responders
if their LVESV was reduced at follow-up by at least
≥ 15% compared with baseline indicating reverse
remodelling [6, 7]. Patients were defined as non-
-responders if their LVESV at follow-up remained
unchanged or was reduced by < 15% compared with
baseline.
Diastolic filling time was defined as the time
between the onset of the E wave and the end of the
A wave by pulsed wave Doppler placed at the mi-
tral valve tips in the apical 4-chamber view.
Pacemaker implantation
After enrolment and baseline assessments, bi-
ventricular devices were implanted as previously
described [6, 9]. Briefly, the LV pacing lead was
inserted transvenously via the subclavian vein with
the help of a guiding catheter into the coronary
sinus, and then positioned in the lateral or postero-
lateral cardiac vein when possible. LV lead was in-
serted in the lateral or posterolateral vein in
39 patients (81%), while in the remaining patients
it was inserted in the anterior vein. The atrioven-
tricular delay was echocardiographically optimized
to obtain the longest filling time or the best myo-
cardial performance index one week after implan-
tation [10, 11].
All patients included in the study underwent
CRT alone or in combination with an implanta-
ble cardioverter-defibrillator over a 12 month
period.
Data analysis
Statistical analysis was performed using a soft-
ware program (SPSS for Windows, SPSS Inc., Chi-
cago, Illinois, USA, version 13.0). All values were
log-transformed due to their non-normal distribu-
tion. In addition, data are presented as mean ± SD.
Baseline categorical data were compared by means
of the Fisher exact test. To compare continuous
variables, the Student’s t-test for normally distri-
buted paired and unpaired data was used, and the
Mann-Whitney or Wilcoxon test for non-paramet-
ric data, when appropriate. Data not normally dis-
tributed was analyzed by the Mann-Whitney test.
Linear regression analysis using Pearson c2 was
used to evaluate the relationship between the se-
verity of disease in terms of functional status and
LV remodelling with neurohormones and cytokines
at baseline. Correlations were controlled for renal
function, age and medication dosage. Linear regres-
sion was also performed to assess the relation be-
tween changes in echocardiographic parameters and
plasma levels of all measured parameters that va-
ried significantly between baseline and follow-up.
For all tests, a two-tailed p value < 0.05 was con-
sidered significant.
Results
Table 1 shows the baseline characteristics of
study participants. Six patients (four non-respond-
ers and two responders) commenced therapy with
beta-blockers during the 1-year study period. Twen-
ty-seven (57%) patients responded to CRT as indi-
cated by a LVESV reduction of at least 15% (re-
sponders).
Table 1. Demographic characteristics of the study participants.
All participants Non-responders Responders P
(n = 47)  (n = 20)  (n = 27)
Age (years) 71.02±9.16 69.30±9.68 72.30±8.72 NS
Body mass index [kg/m2] 25.85±3.31 25.79±2.96 25.90±3.60 NS
Males/females 27/20 11/9 16/11 NS
CrCl [mL/min/1.73 m2] 49.29±15.42 52.41±14.74 46.98±15.77 NS
Etiology (%)
Non ischemic 53.19 60 48 NS
ACE-inhibitors (%) 100 100 100 NS
Beta-blockers (%) 68 60 74 NS
Diuretics (%) 97 97 97 NS
Spironolactone (%) 53 55 52 NS
ICD (%) 42 33 48 NS
ICD — implantable cardioverter-defibrillator;  ACE — angiotensin-converting enzyme
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Figure 2. Correlation between adiponectin and N-terminal-pro-brain natriuretic peptide (NT-proBNP) at baseline (A)
and at follow-up (B).
A B
Baseline adiponectin levels correlated positively
with end-diastolic volumes index (EDVi; r2 = 0.15,
p = 0.031) and end-systolic volumes index (ESVi;
r2 = 0.17, p = 0.021) at baseline in all study partici-
pants (Fig. 1). A positive correlation between adipo-
nectin and NT-proBNP was detectable in non-re-
sponders both at baseline (r2 = 0.73, p < 0.001) and
at follow-up (r2 = 0.25, p = 0.025) respectively (Fig. 2).
Figure 1. Correlation between adiponectin and end-diastolic volumes (EDV) and end-systolic volumes (ESV) indices
at baseline (A) and at follow-up (B).
A B
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No correlation between adiponectin and NT-proBNP
was observed among responders. Baseline plasma
levels of all other measured parameters did not cor-
relate with the CHF functional class status or LV
remodelling (as indicated by LVEDVi and LVESVi
modifications) even after correction for renal func-
tion, age and medication dosage. After 12 months of
CRT, reduction of QRS duration (p < 0.05), improved
functional status (as indicated by NYHA class) and
QoL (p < 0.01 for both), and increased WT (p < 0.01)
were observed in both responders and non-respond-
ers compared with their baseline (Table 2).
After 12 months of CRT, increased IFG-1a lev-
els (p = 0.019) and decreased adiponectin and angio-
tensin II levels (p = 0.029 and p = 0.005, respec-
tively) were observed in all study participants
(Table 3). No significant changes in levels of nore-
pinephrine, TNFa, sTNFR1 and sTNFR2 were ob-
served in any participants after 12 months of CRT.
After 12 months of CRT, levels of NT-proBNP
increased in non-responders (p = 0.031) whereas
levels of angiotensin II decreased in responders
(p = 0.01) compared with their baseline. Levels of
all other measured markers of inflammation re-
mained unchanged in responders and non-respond-
ers compared with their baseline.
Discussion
The present study examined the effect of
12 months of CRT on markers of systemic inflam-
mation in patients with CHF. The major finding of
this study is that long-term CRT decreases activa-
tion of renin–angiotensin system (RAS) in CHF pa-
tients with CRT-related reverse remodelling. In
contrast, activation of RAS remained unchanged in
CHF patients without reverse remodelling. Long-
-term CRT failed to prevent a decline in adiponec-
tin levels in CHF patients regardless of the pres-
ence of reverse remodelling.
Levels of NT-proBNP remained unchanged in
CHF patients with reverse remodelling, whereas
its levels increased in those without reverse remod-
elling, suggesting a possible beneficial role of CRT
in preventing progression of heart failure. Levels
of IGF-1a increased with CRT, whereas CRT had
no effect on plasma levels of ANP and inflammato-
ry markers (TNFa, sTNFR1, sTNFR2 and IL-6).
Cardiac angiotensin formation is increased in
HF [12] and angiotensin is an important modulator
of cardiac remodelling in response to pathologic load
or ischemic myocardial damage [13–15]. Our find-
ings of decreased angiotensin II levels in CHF pa-
tients with CRT-related reverse remodelling cor-
roborate these reports, since no change was ob-
served in non-responders.
Baseline levels of adiponectin in our study were
comparable with those reported previously [16, 17].
Long-term CRT was associated with a significant
decline in plasma adiponectin levels in all partici-
pants, regardless of the presence of reverse remod-
elling. Adiponectin, a collagen-like plasma protein,
with anti-inflammatory and antiatherogenic proper-
ties [18, 19] plays an important role in the develo-
pment of atherosclerosis [20, 21]. Plasma concen-
trations of adiponectin are reduced in obesity [22],
type 2 diabetes [23], hypertension [24] and coro-
nary artery disease [17, 25].
Conversely, high adiponectin levels were pre-
dictors of mortality in HF [25]. Although the mecha-
nisms underlying this association remain unclear,
plasma levels of adiponectin appear to be predomi-
nantly regulated by cardiac natriuretic peptides such
as BNP in HF [26, 27]. Recent reports suggest that
BNP increases adiponectin mRNA in cultured adi-
pocytes and that plasma levels of cGMP, a second
messenger of cardiac natriuretic peptides, correlat-
ed with the plasma adiponectin levels in patients
with CHF [26]. We observed a direct relation be-
tween NT-proBNP and adiponectin in the non-re-
sponder group alone. Non-responders had increased
levels of NT-proBNP and a smaller decline in adi-
ponectin levels after 1-year CRT associated with no
significant changes in LV diameters.
Long-term CRT was associated with increased
IGF-1a in our patients, regardless of reverse re-
modelling. In addition, a reduction in angiotensin II
was associated with an increase in IGF-1a, corrob-
orating the previously described inverse relation-
ship between angiotensin II and IGF-1a in HF [28–
–30]. Low IGF-1a level is a risk factor for incident
CHF among the elderly in the Framingham Heart
Study [31]. Low-normal IGF-1a levels are associated
with increased risk of acute myocardial infarction,
ischemic heart disease, coronary and carotid artery
atherosclerosis and stroke, as well as progression of
CHF [32–34] Levels of IGF-1a are elevated in mild
to moderate HF and lowered in severe symptomatic
HF [35]. Three-month CRT therapy increases plas-
ma IGF-1a levels and improves quality of life in HF,
suggesting that IGF-1a may play a role as a media-
tor in the early phase of symptomatic improvement
after CRT [28].
Levels of BNP increased in non-responders but
remained unchanged in responders, suggesting
a progression of HF in non-responders to CRT.
Greater levels of BNP prior to implantation predict
a positive response to CRT in HF [36]. Levels of
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ANP and BNP consistently decrease after a 3-month
CRT compared with baseline [5, 7, 37]. However,
the Cardiac Resynchronization-Heart Failure Trial
reported a sustained reduction in levels of natriu-
retic peptides at 18-month follow-up, while other
investigators have reported a return to baseline
levels at 12-month follow-up [5, 37]. Further stud-
ies are needed to resolve the question of sustaina-
bility of CRT-related early reduction in BNP levels
in HF.
Lack of effect of CRT on plasma levels of in-
flammatory markers such as TNFa, sTNFR1,
sTNFR2 and IL-6 is in agreement with the docu-
mented no change in TNFa and IL-6 levels after
three and 12 months of CRT therapy [5].
There is no established single definition of re-
sponders and non-responders after CRT therapy
and the criteria of patient selection are still under
debate. After publication of the PROSPECT (Pre-
dictors of Response to CRT) trial, the use of
echocardiography to assess mechanical dyssynchro-
ny and as a possible aid for selecting patients for
cardiac resynchronization therapy has been criti-
cized [38–42].
On the other hand, Yu et al. [41] documented
that a reduction in LVESV of 10% was a strong pre-
dictor of lower long-term mortality and heart fail-
ure events. Recently, Ypenburg et al. [42] found that
more reverse remodelling was associated with less
heart failure hospitalizations and lower mortality
during long-term follow-up, while the negative re-
sponder group had a markedly lower survival rate.
The arguments in favour of identifying non-re-
sponders are still powerful, not only to prevent un-
necessary harm to patients, but also because of the
link between CRT-induced LV remodelling and mor-
tality. Further studies are needed to identify a com-
bination of methods able to find the site of latest
mechanical activation, myocardial scar localization,
and assessing venous anatomy pre-operatively, thus
helping to identify those patients who would not
derive any benefit from (or whose condition could
potentially be worsened by) device implantation.
Conclusions
Long-term CRT is associated with decreased
RAS activation and stabilization of plasma BNP lev-
els in HF patients with reverse LV remodelling.
Long-term CRT, with or without reverse LV re-
modelling, does not affect systemic inflammation
and fails to prevent decline in plasma levels of adi-
ponectin. Our findings underline the complexity of
the interactions between the clinical effects of car-
diac resynchronization, LV remodelling and the
neurohormonal milieu.
Acknowledgements
The authors do not report any conflict of inter-
est regarding this work.
References
1. Cazeau S, Leclercq C, Lavergne T et al. Effects of multisite
biventricular pacing in patients with heart failure and intraven-
tricular conduction delay. N Engl J Med, 2001; 344: 873–880.
2. Gullestad L, Aukrust P. Review of trials in chronic heart failure
showing broad-spectrum anti-inflammatory approaches. Am
J Cardiol, 2005; 95: 17C–23C.
3. Rubaj A, Rucinski P, Rejdak K et al. Biventricular versus right
ventricular pacing decreases immune activation and augments
nitric oxide production in patients with chronic heart failure.
Eur J Heart Fail, 2006; 8: 615–620.
4. Theodorakis GN, Flevari P, Kroupis C et al. Anti-infammatory
effects of cardiac resynchronization therapy in patients with
chronic heart failure. Pacing Clin Electrophysiol, 2006; 29: 255–261.
5. Boriani G, Regoli F, Saporito D et al. Neurohormones and in-
fammatory mediators in patients with heart failure undergoing
cardiac resynchronization therapy: Time courses and prediction
of response. Peptides, 2006; 27: 1776–1786.
6. Michelucci A, Ricciardi G, Sofi F et al. Relation of inflammatory
status to major adverse cardiac events and reverse remodeling
in patients undergoing cardiac resynchronization therapy. J Card
Fail, 2007; 13: 207–210.
7. Yu CM, Bleeker GB, Fung JWH et al. Left ventricular reverse
remodeling but not clinical improvement predicts long-term sur-
vival after cardiac resynchronization therapy. Circulation, 2005;
112: 1580–1586.
8. Lang RM, Bierig M, Devereux RB et al Recommendations for
Chamber Quantification: A Report from the American Society of
Echocardiography’s Guidelines and Standards Committee and
the Chamber Quantification Writing Group, Developed in Con-
junction with the European Association of Echocardiography,
a Branch of the European Society of Cardiology. J Am Soc
Echocardiogr, 2005; 18: 1440–1463.
9. Lilli A, Ricciardi G, Porciani MC et al Cardiac resynchronization
therapy: Gender related differences in left ventricular reverse
remodeling. Pacing Clin Electrophysiol, 2007;30: 1349–1355.
10. Kindermann M, Frolhig G, Doerr T, Schieffer H. Optimizing the
AV delay in DDD pacemaker patients with high degree AV block:
Mitral valve Doppler versus impedance cardiography. Pacing Clin
Electrophysiol, 1997; 20: 2453–2462.
11. Porciani MC, Dondina C, Macioce R et al. Echocardiographic
examination of atrioventricular and interventricular delay opti-
mization in cardiac resynchronization therapy. Am J Cardiol,
2005; 95: 1108–1110.
12. Lee CS, Tkacs NC. Current concepts of neurohormonal activa-
tion in heart failure: Mediators and mechanisms. AACN Adv
Crit Care, 2008; 19: 364–385.
13. Aras O, Messina SA, Shirani J, Eckelman WC, Dilsizian V. The
role and regulation of cardiac angiotensin-converting enzyme
for noninvasive molecular imaging in heart failure. Curr Cardiol
Rep, 2007; 9: 150–158.
552
Cardiology Journal 2009, Vol. 16, No. 6
www.cardiologyjournal.org
14. Neri Serneri GG, Boddi M, Modesti PA et al. Increased cardiac
sympathetic activity and insulin-like growth factor-I formation
are associated with physiological hypertrophy in athletes. Circ
Res, 2001; 89: 977–982.
15. Neri Serneri GG, Boddi M, Coppo M et al. Evidence for the
existence of a functional cardiac renin-angiotensin system in
humans. Circulation, 1996; 94: 1886–1893.
16. Tamura T, Furukawa Y, Taniguchi R et al. Serum adiponectin
level as an independent predictor of mortality in patients with
congestive heart failure. Circ J, 2007; 71: 623–630.
17. Tarquini R, Lazzeri C, Laffi G, Gensini GF. Adiponectin and the
cardiovascular system: from risk to disease. Intern Emerg Med,
2007; 2: 165–176.
18. Takano H, Obata JE, Kodama Y et al. Adiponectin is released
from the heart in patients with heart failure. Int J Cardiol, 2009;
132: 221–226.
19. Weyer C, Funahashi T, Tanaka S et al. Hypoadiponectinemia in
obesity and type 2 diabetes: close association with insulin re-
sistance and hyperinsulinemia. J Clin Endocrinol Metab, 2001;
86: 1930–1935.
20. Furuhashi M, Ura N, Higashiura K et al. Blockade of the renin–
–angiotensin system increases adiponectin concentrations in pa-
tients with essential hypertension. Hypertension, 2003; 42: 76–81.
21. Arita Y, Kihara S, Ouchi N et al. Adipocyte-derived plasma pro-
tein adiponectin acts as a platelet-derived growth factor-BB-
-binding protein and regulates growth factor-induced common
postreceptor signal in vascular smooth muscle cell. Circulation,
2002; 105: 2893–2898.
22. Baratta R, Amato S, Degano C et al. Adiponectin relationship
with lipid metabolism is independent of body fat mass: Evidence
from both cross-sectional and intervention studies. J Clin Endo-
crinol Metab, 2004; 89: 2665–2671.
23. Hotta K, Kiura K, Tabata M et al. Plasma concentrations of
a novel, adipose-specific protein, adiponectin, in type 2 diabetic
patients. Artioscler Thromb Vasc Biol, 2000; 20: 1595–1599.
24. Ouchi N, Kihara S, Arita Y et al. Novel modulator for endothelial
adhesion molecules: Adipocyte-derived plasma protein adiponec-
tin. Circulation, 1999; 100: 2473–2476.
25. Kistorp C, Faber J, Galatius S et al. Plasma adiponectin, body
mass index, and mortality in patients with chronic heart failure.
Circulation, 2005; 112: 1756–1762.
26. Tsutamoto T, Tanaka T, Sakai H et al. Total and high molecular
weight adiponectin, haemodynamics, and mortality in patients
with chronic heart failure. Eur Heart J, 2007; 28: 1723–1730.
27. Tanaka T, Tsutamoto T, Nishiyama K et al. Impact of oxidative
stress on plasma adiponectin in patients with chronic heart fail-
ure. Circ J, 2008; 72: 563–568.
28. Molon G, Adamo E, De Ferrari GM et al. Effects of cardiac
resynchronization therapy on insulin-like growth factor-1 in pa-
tients with advanced heart failure. J Cardiovasc Med (Hagers-
town), 2007; 8: 917–922.
29. Brink M, Wellen J, Delafontaine. Angiotensin II cause weight
loss and decreases circulating insulin-like growth factor I in rats
through a pressor-independent mechanism. J Clin Invest, 1996;
97: 2509–2516
30. Corbalan R, Acevedo M, Godoy I, Jalil J, Campusano C, Klassen J.
Enalapril restores depressed circulating insulin-like growth fac-
tor 1 in patients with chronic heart failure. J Card Fail, 1998; 4:
115–119.
31. Vasan RS, Sullivan LM, D’Agostino RB et al. Serum insulin-like
growth factor I and risk for heart failure in elderly individuals
without a previous myocardial infarction: The Framingham
Heart Study. Ann Intern Med, 2003; 139: 642–648.
32. Kaplan RC, McGinn AP, Pollak MN et al. Association of total
insulin-like growth factor-I, insulin-like growth factor binding
protein-1 (IGFBP-1), and IGFBP-3 levels with incident coro-
nary events and ischemic stroke. J Clin Endocrinol Metab, 2007;
92: 1319–1325.
33. Johnsen SP, Hundborg HH, Sørensen HT et al. Insulin-like
growth factor (IGF)-I, -II, and IGF binding protein-3 and risk of
ischemic stroke. J Clin Endocrinol Metab, 2005; 90: 5937–5941.
34. Colao A. The GH-IGF-I axis and the cardiovascular system:
Clinical implications. Clin Endocrinol (Oxford), 2008; 69: 347–358
35. Al-Obaidi MK, Hon JK, Stubbs PJ et al. Plasma insulin-like
growth factor-1 elevated in mild-to-moderate but not severe
heart failure. Am Heart J, 2001; 142: E10.
36. Lellouche N, De Diego C, Cesario DA et al. Usefulness of pre-
implantation B-type natriuretic peptide level for predicting re-
sponse to cardiac resynchronization therapy. Am J Cardiol,
2007; 99: 242–246.
37. Uretsky BF,, Thygesen K,, Daubert JC et al. Predictors of mortality
from pump failure and sudden cardiac death in patients with
systolic heart failure and left ventricular dyssynchrony: Results
of the CARE-HF trial. J Card Fail, 2008; 14: 670–675.
38. Sanderson JE. Echocardiography for cardiac resynchronization
therapy selection: fatally flawed or misjudged? J Am Coll Cardiol,
2009; 53: 1960–1964.
39. Hawkins NM, Petrie MC, Burgess MI, McMurray JJV. Selecting
patients for cardiac resynchronization therapy: The fallacy of
echocardiographic dyssynchrony. J Am Coll Cardiol, 2009; 53:
1944–1959.
40. Chung ES, Leon AR, Tavazzi L et al. Results of the Predictors of
Response to CRT (PROSPECT) trial. Circulation, 2008; 117:
2608–2616.
41. Bax JJ, Gorcsan J 3rd. Echocardiography and noninvasive imaging
in cardiac resynchronization therapy: Results of the PROSPECT
(Predictors of Response to Cardiac Resynchronization Therapy)
study in perspective. J Am Coll Cardiol, 2009; 53: 1933–1943.
42. Ypenburg C, van Brommerl RJ, Borleffs JW et al. Long-term
prognosis after cardiac resynchronization therapy is related to
the extent of left ventricular reverse remodeling at midterm
follow-up. J Am Coll Cardiol, 2009; 53: 483–490.
